Sex Selection Goes Mainstream
By Marcy Darnovsky,
Alternet
| 09. 25. 2003
Several times over the past few months, a small but striking ad from a Virginia-based fertility clinic has appeared in the Sunday Styles section of the New York Times. Alongside a smiling baby, its boldface headline asks, "Do You Want To Choose the Gender Of Your Next Baby?"
If so, the ad continues, you can join "prospective parents...from all over the world" who come to the Genetics & IVF Institute (GIVF) for an "exclusive scientifically-based sperm sorting gender selection procedure." The technique, known by the trademarked name MicroSort, is offered as a way to choose a girl or boy either for the "prevention of genetic diseases" (selecting against the sex affected by an X-linked or Y-linked condition) or for "family balancing" (selecting for a girl in a family that already has one or more boys, or vice versa).
GIVF has been promoting MicroSort on its Web site for several years, and a few other fertility clinics offer other "family balancing" methods online. But the MicroSort ads in the New York Times represent a bolder and higher-profile approach. They mark...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...